gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · IDYAHealthcarePharmaceuticals

IDEAYA Biosciences, Inc. Common Stock (IDYA)

$32.36+3.29%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$31.75▲ 1.24% in range
Nov 3, 2025Low $27.60 · High $42.48Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

IDEAYA Biosciences closed at $32.36 on Nov 4, up 3.29%, 23.8% below its 52-week closing high. Volume of 2.0M shares was 2.17× its 20-day average (well above normal).

Split-adjusted performance: -11.7% over one month, +12.6% over six months, +3.2% over one year.

In the quarter ended Sep 30, 2026, revenue was $10.24M, down 95.1% from a year earlier, with a net margin of -1227.8%.

Short interest was 9.1M shares at the Oct 15 settlement, down 1.1% from the prior report (10.4% of float, 12.0 days to cover).

Market cap$3.12B96.5M shares
Revenue · quarter$10.2M−95.1% YoY
Diluted EPS$-1.22−191.7% YoY
P/E · TTM—P/S 85.5×
Net margin-1,227.8%Gross 100.0%
Dividend yieldNone
52-week range27.60 – 42.48−23.8% from high
Volume2.0M2.17× 20-day avg
Volatility · 60d37.7%Annualised
Short % of float10.4%12.0 days to cover
Net cash$838.5MCash $838.5M
Next earnings—Not scheduled
Split-adjusted performance
1W −4.7%1M −11.7%3M −10.7%6M +12.6%YTD −6.4%1Y +3.2%3Y +25.6%5Y +50.0%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum78
Revenue growth11
Net margin19
Value (low P/E)—
Size85

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short9.1M−1.1% vs prior
Days to cover12.0Settled Oct 15
% of float10.4%
Short vol. 10d56.4%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
IDYAIDEAYA Biosciences$32.36+3.29%+12.6%−95.1%−1227.8%—$3.12B
BHCBausch Health Companies$8.34+2.46%+47.6%+9.7%14.8%—$3.12BCompare
VRDNViridian Therapeutics$29.06+15.53%+65.7%+278.7%−39726.8%—$3.29BCompare
ELVNEnliven Therapeutics$47.25+5.40%+14.7%———$3.46BCompare
DYNDyne Therapeutics$18.54+2.71%−1.6%———$3.46BCompare
VKTXViking Therapeutics$27.97+7.21%−13.4%———$3.57BCompare
OGNOrganon &$13.83−0.14%+3.1%−1.7%10.4%17.1$3.63BCompare
AMLXAmylyx Pharmaceuticals$29.40+0.68%+83.1%———$3.69BCompare
IRONDisc Medicine$83.28+2.61%+21.3%———$3.70BCompare

News about IDEAYA Biosciences

All news →
IDEAYA Biosciences, Inc. (IDYA) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research · 1d agoNeutralIDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research · Oct 27, 2026▲ PositiveIDEAYA Eye Cancer Trial Data Beats Standard Therapy, Stock SoarsBenzinga · Apr 13, 2026▲ Positive

Quick answers

What does IDEAYA Biosciences do?
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies.
What is IDYA's market cap?
$3.12B, based on the Nov 4 close of $32.36.
Does IDEAYA Biosciences pay a dividend?
No regular cash dividend has been paid in the last year.
How much of IDYA is sold short?
9.1M shares, 10.4% of float, as of Oct 15, 2026.
What sector is IDYA in?
Healthcare, in the Pharmaceuticals industry.

About IDEAYA Biosciences

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

HQ: South San Francisco, CA145 employeesListed May 23, 2019ideayabio.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology